Journal
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
Volume 61, Issue 5, Pages -Publisher
AMER SOC MICROBIOLOGY
DOI: 10.1128/AAC.02534-16
Keywords
KPC; ceftazidime-avibactam; drug resistance mechanisms; site-directed mutagenesis
Categories
Funding
- National Institutes of Health [UM1AI104681, R21AI288338, R21AI111037, K08AI114883]
Ask authors/readers for more resources
We identified four bla(KPC-3) mutations in ceftazidime-avibactam-resistant clinical Klebsiella pneumoniae isolates, corresponding to D179Y, T243M, D179Y/T243M, and EL165-166 KPC-3 variants. Using site-directed mutagenesis and transforming vectors into Escherichia coli, we conclusively demonstrated that mutant bla(KPC-3) encoded enzymes that functioned as extended-spectrum beta-lactamases; mutations directly conferred higher MICs of ceftazidime-avibactam and decreased the MICs of carbapenems and other beta-lactams. Impact was strongest for the D179Y mutant, highlighting the importance of the KPC Omega-loop.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available